Early Targeted Combination Treatment With Conventional Synthetic Disease‐Modifying Antirheumatic Drugs and Long‐Term Outcomes in Rheumatoid Arthritis: Ten‐Year Follow‐Up Results of a Randomized Clinical Trial
暂无分享,去创建一个
P. Hannonen | T. Möttönen | H. Kautiainen | L. Laasonen | M. Leirisalo-Repo | J. Koski | M. Kauppi | T. Uutela | T. Yli-Kerttula | O. Kaipiainen-Seppänen | V. Rantalaiho | H. Julkunen | T. Malmi | T. Sandström
[1] J. Askling,et al. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden , 2017, JAMA internal medicine.
[2] C. Strehl,et al. Will we ever have better glucocorticoids? , 2017, Clinical immunology.
[3] T. Möttönen,et al. Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials. , 2016, Clinical and experimental rheumatology.
[4] S. Ajeganova,et al. Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study , 2016, Scandinavian journal of rheumatology.
[5] P. Hannonen,et al. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis , 2016, The Journal of Rheumatology.
[6] T. Stijnen,et al. Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment , 2016, Annals of Internal Medicine.
[7] D. Furst,et al. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. , 2015, Rheumatology.
[8] G. Haugeberg,et al. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway , 2015, Arthritis Research & Therapy.
[9] M. Hochberg,et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis , 2015, Arthritis Research & Therapy.
[10] J. Katz,et al. Sociodemographic, Disease, Health System, and Contextual Factors Affecting the Initiation of Biologic Agents in Rheumatoid Arthritis: A Longitudinal Study , 2014, Arthritis care & research.
[11] C. Lanzani,et al. AB0176 Association between Polymorphisms in Beta-Adducin and Sodium/Calcium Exchanger 1 and SLE with and without Nephritis , 2014 .
[12] F. Breedveld,et al. Longterm Effect of Delaying Combination Therapy with Tumor Necrosis Factor Inhibitor in Patients with Aggressive Early Rheumatoid Arthritis: 10-year Efficacy and Safety of Adalimumab from the Randomized Controlled PREMIER Trial with Open-label Extension , 2014, The Journal of Rheumatology.
[13] D. Solomon,et al. Patterns of Disease‐Modifying Antirheumatic Drug Use in Rheumatoid Arthritis Patients After 2002: A Systematic Review , 2013, Arthritis care & research.
[14] P. Hannonen,et al. Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial , 2013, Annals of the rheumatic diseases.
[15] J. Schoones,et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review , 2013, Annals of the rheumatic diseases.
[16] P. Hannonen,et al. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies. Observational data from two rheumatology clinics. , 2013, Clinical and experimental rheumatology.
[17] M. Suarez‐Almazor,et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. , 2012, JAMA.
[18] P. Hannonen,et al. Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study) , 2012, Annals of the rheumatic diseases.
[19] P. Hannonen,et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial , 2010, Arthritis research & therapy.
[20] Maurizio Cutolo,et al. Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.
[21] P. Hannonen,et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. , 2009, Arthritis and rheumatism.
[22] Olivier Meyer,et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study , 2008, Arthritis Research & Therapy.
[23] H. Mäkinen,et al. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. , 2006, Clinical and experimental rheumatology.
[24] T. Saxne,et al. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis , 2003, Annals of the rheumatic diseases.
[25] van der Heijde Dm,et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .
[26] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[27] M. A. van 't Hof,et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.